Description
A triple agonist of GLP-1, GIP, and glucagon receptors (LY3437943). Retatrutide has demonstrated unprecedented weight loss (~24% in 48 weeks in humans) by combining the effects of GLP-1/GIP (insulin secretion, appetite suppression) with glucagon’s increase of energy expenditure[23][24]. 5 mg vials are for initial testing. In obese rodent studies, retatrutide drastically improves glucose tolerance, induces fat oxidation, and even reduces liver fat and fibrosis due to its glucagon activity.
20 mg kit. This dose is approaching the upper end used in phase-2 human trials. In animal research it yields profound metabolic changes: extremely low adiposity, improved insulin sensitivity, and even regeneration of pancreatic islets has been noted. Long-term high-dose retatrutide studies will clarify if there are any adaptive counter-regulatory mechanisms triggered by such potent weight reduction.




Reviews
There are no reviews yet.